|
시장보고서
상품코드
2026381
2형 당뇨병 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 투여 경로별, 인구통계별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Type 2 Diabetes Market Size, Share, and Growth Analysis, By Drug Class (Insulin, DPP-4 Inhibitors), By Route of Administration (Oral, Subcutaneous), By Demographics, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 2형 당뇨병 시장 규모는 2024년에 345억 달러로 평가되었고, 2025년 371억 6,000만 달러에서 2033년까지 672억 6,000만 달러로 확대되어 예측 기간(2026-2033년)에 CAGR 7.7%로 성장할 전망입니다.
세계 2형 당뇨병 시장은 당뇨병 유병률 증가에 따라 효과적인 치료법에 대한 수요가 증가하면서 성장세를 보이고 있습니다. 제약사들은 나트륨-포도당 공수송체 2(SGLT2) 억제제, 글루카곤 유사 펩타이드 1(GLP-1) 수용체 작용제 등 부작용을 줄이면서 더 나은 관리 수단을 제공하는 혁신적인 의약품 개발을 통해 시장 성장을 주도하고 있습니다. 그러나 환자들 사이에서 이러한 새로운 치료법에 대한 인지도가 낮다는 점이 보급에 걸림돌이 될 수 있습니다. 증가하는 헬스케어 수요를 충족시키기 위해 업계는 특히 합리적인 가격의 첨단 치료 솔루션을 제공하는 분야에서 큰 확장의 기회를 맞이하고 있습니다. 또한, 모바일 건강 앱과 클라우드 기반 솔루션을 포함한 기술의 발전으로 접근성과 효과성이 향상되어 이 중요한 헬스케어 분야 시장 성장에 더욱 기여하고 있습니다.
세계 2형 당뇨병 시장 성장 요인
세계 2형 당뇨병 시장의 주요 시장 성장 촉진요인 중 하나는 전 세계 인구의 비만과 좌식 생활 습관 증가입니다. 비만율 증가와 함께 2형 당뇨병 발병률도 급증하고 있으며, 효과적인 치료법과 관리 솔루션에 대한 수요가 증가하고 있습니다. 또한, 당뇨병과 그 합병증에 대한 인식 증가와 더불어 기술 및 의약품 개발의 발전은 당뇨병 치료의 혁신을 주도하고 있습니다. 헬스케어 시스템이 당뇨병 증가하는 부담에 대응하기 위해 노력하는 가운데, 연구개발에 대한 투자와 신약 및 신의료기기의 도입이 시장 성장을 더욱 촉진하고 있습니다.
세계 2형 당뇨병 시장 성장 억제요인
세계 2형 당뇨병 시장의 주요 시장 성장 억제요인 중 하나는 생활습관병 유병률 증가입니다. 이로 인해 당뇨병 관리와 치료 순응이 어려워지는 경우가 많습니다. 비만, 심혈관 질환, 대사증후군으로 고통받는 사람들이 늘어남에 따라 종합적인 건강관리에 대한 관심이 높아짐에 따라 당뇨병에 특화된 치료법에 대한 관심과 자원이 분산될 수 있습니다. 또한, 당뇨병 치료제 및 의료기기에 소요되는 고가의 비용은 의료 예산을 압박하여 치료 중단 및 불충분한 질병 관리로 이어질 수 있습니다. 이러한 요인들이 복합적으로 작용하여 필요한 치료에 대한 접근성을 제한하고 궁극적으로 2형 당뇨병 관리에서 환자의 결과에 영향을 미침으로써 시장 성장을 저해할 수 있습니다.
세계 2형 당뇨병 시장 동향
세계 2형 당뇨병 시장에서는 질병 관리에 대한 기술 의존도가 높아짐에 따라 원격 모니터링 및 디지털 헬스 솔루션으로의 전환이 진행되고 있습니다. 혁신적인 웨어러블 기기 및 모바일 애플리케이션를 통해 환자는 혈당 수치를 지속적으로 모니터링하고 실시간 데이터를 의료진과 공유할 수 있습니다. 이러한 예방적 접근 방식은 복약 순응도를 높이고 전반적인 건강 상태를 추적하여 치료의 질과 환자 참여도를 높입니다. 그 결과, 이러한 기술의 활용은 의료 비용을 절감하고 더 나은 건강 결과를 가져다 줄 것으로 예상되며, 2형 당뇨병 관리에 디지털 헬스 통합의 견고한 추세를 보이고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 2형 당뇨병 시장 규모 : 약제 클래스별
세계의 2형 당뇨병 시장 규모 : 투여 경로별
세계의 2형 당뇨병 시장 규모 : 인구통계별
세계의 2형 당뇨병 시장 규모 : 유통 채널별
세계의 2형 당뇨병 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.05.26Global Type 2 Diabetes Market size was valued at USD 34.5 Billion in 2024 and is poised to grow from USD 37.16 Billion in 2025 to USD 67.26 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).
The global type 2 diabetes market is propelled by the increasing prevalence of the condition, leading to heightened demand for effective treatment options. Pharmaceutical companies are driving market growth through the development of innovative drugs, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, which offer better management options with reduced side effects. However, the lack of awareness regarding these new treatments among patients may hinder their widespread acceptance. In response to rising medical needs, the industry faces significant opportunities for expansion, particularly in providing affordable and advanced treatment solutions. Additionally, technological advancements, including mobile health applications and cloud-based solutions, are enhancing accessibility and effectiveness, further contributing to market growth in this critical healthcare segment.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Type 2 Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Type 2 Diabetes Market Segments Analysis
Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Demographics, Distribution Channel and region. Based on Drug Class, the market is segmented into Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Others. Based on Route of Administration, the market is segmented into Oral, Subcutaneous and Inhalation. Based on Demographics, the market is segmented into Age Group and Gender. Based on Distribution Channel, the market is segmented into Online Pharmacies, Hospital Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Type 2 Diabetes Market
One of the key market drivers for the global type 2 diabetes market is the increasing prevalence of obesity and sedentary lifestyles among populations worldwide. As obesity rates rise, the incidence of type 2 diabetes has escalated, leading to higher demand for effective treatment options and management solutions. Additionally, heightened awareness of the disease and its complications, coupled with advancements in technology and drug development, is driving innovation in diabetes care. As healthcare systems strive to manage the growing burden of diabetes, investment in research and the introduction of new medications and devices are further propelling market growth.
Restraints in the Global Type 2 Diabetes Market
One key market restraint for the global type 2 diabetes market is the increasing prevalence of lifestyle-related diseases, which often complicate diabetes management and treatment adherence. As more individuals suffer from obesity, cardiovascular issues, and metabolic syndrome, the focus on holistic health management may divert attention and resources from diabetes-specific therapies. Additionally, the high costs associated with diabetes medications and devices can strain healthcare budgets, leading to treatment discontinuation and poor disease management. These factors combined could hinder growth by limiting access to necessary therapies and ultimately affecting patient outcomes in managing type 2 diabetes.
Market Trends of the Global Type 2 Diabetes Market
The Global Type 2 Diabetes market is experiencing a significant shift towards remote monitoring and digital health solutions, reflecting an increasing reliance on technology for disease management. Innovative wearable devices and mobile applications empower patients to continuously monitor their glucose levels and share real-time data with healthcare providers. This proactive approach facilitates improved medication adherence and overall health tracking, enhancing care quality and patient engagement. As a result, the utilization of these technologies is projected to drive better health outcomes while simultaneously lowering healthcare costs, indicating a robust trend towards integrating digital health in the management of Type 2 diabetes.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Type 2 Diabetes Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Insulin
- DPP-4 Inhibitors
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
- Others
Global Type 2 Diabetes Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Subcutaneous
- Inhalation
Global Type 2 Diabetes Market Size by Demographics & CAGR (2026-2033)
- Market Overview
- Age Group
- 18-39
- 40-49
- 50-59
- Above 60
- Gender
- Male
- Female
Global Type 2 Diabetes Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Global Type 2 Diabetes Market Size & CAGR (2026-2033)
- North America (Drug Class, Route of Administration, Demographics, Distribution Channel)
- US
- Canada
- Europe (Drug Class, Route of Administration, Demographics, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Route of Administration, Demographics, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Route of Administration, Demographics, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Route of Administration, Demographics, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dexcom, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insulet Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
